The non-clinical program for toxicology- and safety studies of Lipum’s candidate drug (SOL-116) has been carried out in collaboration with the contract research organisation (CRO) Charles River Laboratories. They have now released the final report of the last study of the program concluding the results from the 13-week Good Laboratory Practice (GLP) compliant study initiated in September last year.
In conclusion, the overall nonclinical toxicity and safety program shows SOL-116 to be well-tolerated and with no adverse effects at dose levels well above those expected to be efficacious in man. Moreover, the high specificity towards the target, which is an advantage of antibody drugs, was confirmed.
"Another milestone has been reached and we are indeed pleased with the results that, as expected, confirms the safety and tolerability of our antibody SOL-116. We are now looking forward to the start of our first-in-man clinical study later this year.” – says Einar Pontén, CEO.
For further information, please contact:
Lipum AB (publ) is a biopharmaceutical company specialized in discovery and development of a novel treatment for chronic inflammatory diseases. The lead candidate SOL-116 is a humanized antibody designed to provide efficacious therapy by blocking a previously overlooked target molecule of the immune system (BSSL). SOL-116 is in late preclinical stage supported by solid data for the rare disease juvenile idiopathic arthritis and rheumatoid arthritis. Lipum also explores other inflammatory diseases with a high unmet medical need. The company is based in Umeå, an excellent life science cluster in Sweden. Lipum’s unique approach has attracted international attention, including a major European Commission Horizon 2020 grant. The company's share (LIPUM) is traded on the Nasdaq First North Growth Market. Certified Adviser is G&W Fondkommission, email: email@example.com, phone: +46 8 503 000 50.